Gamifant
Sobi
Gamifant is an FDA-approved treatment for primary hemophagocytic lymphohistiocytosis (HLH) in patients with refractory, recurrent, or progressive disease or intolerance to conventional therapy.
Gamifant works by binding to soluble and receptor-bound forms of target interferon-gamma (IFNy) to neutralize its activity to block intracellular signaling to inhibit macrophage activation and the downstream release of pro-inflammatory cytokines.
Common side effects include infections, high blood pressure, infusion-related reactions and fever.
